advertisement
Stewart WC 7
Showing records 1 to 7 | Display all abstracts from Stewart WC11307 Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy
Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
Eye 2004; 18: 990-995
11300 Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%
Konstas AGP; Kozobolis VP; Lallos N; Christodoulakis E; Stewart JA; Stewart WC
Eye 2004; 18: 1264-1269
11228 Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma
Konstas AGP; Mylopoulos N; Karabatsas CH; Kozobolis VP; Diafas S; Papapanos P; Georgiadis N; Stewart WC
Eye 2004; 18: 893-899
11422 A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension
Day DG; Schacknow PN; Sharpe ED; Ellyn JC; Kulze III JC; Threlkeld AB; Jones ED; Brown RH; Jenkins JN; Stewart WC
Journal of Ocular Pharmacology and Therapeutics 2004; 20: 383-392
11415 Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments
Haverkamp F; Wuensch S; Fuchs M; Stewart WC
European Journal of Ophthalmology 2004; 14: 407-415
11448 Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies
Konstas AGP; Banyai L; Blask K-D; Vath J; Kozobolis VP; Trub PR; Tsironi S; Maloutas S; Teus MA; Stewart WC
Journal of Ocular Pharmacology and Therapeutics 2004; 20: 375-382
11505 Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects
Stewart WC; Day DG; Stewart JA; Holmes KT; Jenkins JN
Eye 2004; 18: 905-910
